clinical trial · NCT07493265
A Study to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
NarcolepsyE2086Placebo
brief summary
The primary purpose of this study is to evaluate the optimal doses of E2086 compared to placebo in participants with narcolepsy for reduction of excessive daytime sleepiness (EDS) as assessed by Mean Sleep Latency (MSL) (measured from the first 4 maintenance of wakefulness tests \[MWTs\]).
started
Mar 23, 2026
primary completion
Feb 14, 2027
completion
Mar 1, 2027
last updated
Mar 25, 2026
official title
A Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of E2086 in Adults With Narcolepsy
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol